title: Characterization of a recombinant influenza vaccine candidate using complementary LC-MS methods.
abstract: Influenza vaccination is recognized as the most effective method for reducing morbidity and mortality due to seasonal influenza. To improve vaccine supply and to increase flexibility in vaccine manufacturing, cell culture-based vaccine production has emerged to overcome limitations of egg-based production. The switch of production system and the need for annual re-evaluation of vaccines for the effectiveness due to frequent viral antigenic changes call for methods for complete characterization of the hemagglutinin (HA) antigens and the final vaccine products. This study describes advanced liquid chromatography-mass spectrometry (LC-MS) methods for simultaneous identification of HA proteins and process-related impurities in a trivalent influenza candidate vaccine, comprised of purified recombinant HA (rHA) antigens produced in an insect cell-baculovirus expression vector system (BEVS). N-linked glycosylation sites and glycoforms of the three rHA proteins (corresponding to influenza A subtypes H1N1 and H3N2 and B virus, respectively) were profiled by peptide mapping using reversed-phase (RP) LC-MS(E) (data independent acquisition LC-MS using an alternating low and elevated collision energy scan mode). The detected site-specific glycoforms were further confirmed and quantified by hydrophilic interaction LC (HILIC)-multiple reaction monitoring (MRM) assays. LC-MS(E) was used to characterize the vaccine candidate, providing both protein identities and site-specific information of glycosylation and degradations on each rHA protein. HILIC-MRM methodology was used for rapid confirming and quantifying site-specific glycoforms and potential degradations on each rHA protein. These methods can contribute to the monitoring of vaccine quality especially as it pertains to product comparability studies to evaluate the impact of production process changes.
authors.affiliation: Department of Biopharmaceutical Sciences, Waters Corporation, Milford, MA 01757, USA. hongwei_xie@waters.com
authors.forename: Hongwei
authors.initials: H
authors.lastname: Xie
authors.forename: Catalin
authors.initials: C
authors.lastname: Doneanu
authors.forename: Weibin
authors.initials: W
authors.lastname: Chen
authors.forename: Joseph
authors.initials: J
authors.lastname: Rininger
authors.forename: Jeffery R
authors.initials: JR
authors.lastname: Mazzeo
mesh_terms: D000956:Antigens, Viral / Q000032:analysis; D002853:Chromatography, Liquid / Q000379:methods*; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000032:analysis; D007252:Influenza Vaccines / Q000032:analysis*; D013058:Mass Spectrometry / Q000379:methods*; D010449:Peptide Mapping; D011994:Recombinant Proteins / Q000032:analysis; D014614:Vaccines, Synthetic / Q000032:analysis*
chemical_list: D000956:Antigens, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic